Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Jackson

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 27, 2013
Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancerSkyler B Johnson, Daniel A Hamstra, William C Jackson, et al.
Advances in Radiation Oncology|August 12, 2017
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomyWilliam C Jackson, Felix Y Feng, Stephanie Daignault, et al.
Cancer|December 22, 2016
Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancerRobert T Dess, William C Jackson, Simeng Suy, et al.
Advances in Radiation Oncology|November 9, 2017
Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboardsCharles S Mayo, John Yao, Avraham Eisbruch, et al.
Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.
Urologic Oncology|May 8, 2019
The current state of randomized clinical trial evidence for prostate brachytherapyRobert T Dess, Payal D Soni, William C Jackson, et al.
The Journal of Urology|September 11, 2016
Very Early Salvage Radiotherapy Improves Distant Metastasis-Free SurvivalAhmed Abugharib, William C Jackson, Vasu Tumati, et al.
Neurosurgery|September 22, 2019
Local Control and Toxicity of Multilevel Spine Stereotactic Body RadiotherapyWhitney H Beeler, Kelly A Speth, Michael T Broderick, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2018
Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional DamageDaniel Rocky Owen, Phillip S Boonstra, Benjamin L Viglianti, et al.
JNCI Cancer Spectrum|November 17, 2025
Postprostatectomy prostate cancer treated with radiation therapy: adverse features and androgen deprivation therapy use in a statewide consortiumSamuel N Regan, Michael Dykstra, Huiying Yin, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
International Journal of Radiation Oncology, Biology, Physics|July 27, 2013
Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancerSkyler B Johnson, Daniel A Hamstra, William C Jackson, et al.
Advances in Radiation Oncology|August 12, 2017
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomyWilliam C Jackson, Felix Y Feng, Stephanie Daignault, et al.
Cancer|December 22, 2016
Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancerRobert T Dess, William C Jackson, Simeng Suy, et al.
Advances in Radiation Oncology|November 9, 2017
Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboardsCharles S Mayo, John Yao, Avraham Eisbruch, et al.
Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.
Urologic Oncology|May 8, 2019
The current state of randomized clinical trial evidence for prostate brachytherapyRobert T Dess, Payal D Soni, William C Jackson, et al.
The Journal of Urology|September 11, 2016
Very Early Salvage Radiotherapy Improves Distant Metastasis-Free SurvivalAhmed Abugharib, William C Jackson, Vasu Tumati, et al.
Neurosurgery|September 22, 2019
Local Control and Toxicity of Multilevel Spine Stereotactic Body RadiotherapyWhitney H Beeler, Kelly A Speth, Michael T Broderick, et al.
International Journal of Radiation Oncology, Biology, Physics|August 16, 2018
Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional DamageDaniel Rocky Owen, Phillip S Boonstra, Benjamin L Viglianti, et al.
JNCI Cancer Spectrum|November 17, 2025
Postprostatectomy prostate cancer treated with radiation therapy: adverse features and androgen deprivation therapy use in a statewide consortiumSamuel N Regan, Michael Dykstra, Huiying Yin, et al.
Pageof 9